<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05100355</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-2021-07</org_study_id>
    <nct_id>NCT05100355</nct_id>
  </id_info>
  <brief_title>Management of the Lack of Blood Return on a Central Venous Catheter (CVC) Before Chemotherapy</brief_title>
  <acronym>CATAREV-B</acronym>
  <official_title>Management of the Lack of Blood Return on a Central Venous Catheter (CVC) Before Chemotherapy in a Day Unit: Phase III Randomised Multicentre Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PHRC-I</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare two methods of managing the lack of CVC blood return : opacification using contrast&#xD;
      media injection or radio-clinical method with a simple chest X-ray followed by a rapid&#xD;
      infusion of physiological serum&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of CVC is part of daily life in onco-hematology, particularly for chemotherapy&#xD;
      treatments in the Day Unit (DU). Among the possible complications and dysfunctions, the most&#xD;
      frequent is the lack of CVC blood return, which can be responsible for a disorganization of&#xD;
      the patient's management in the Day Unit (delay in patient management).&#xD;
&#xD;
      In this study, the 2 most commonly used schemes are compared in a randomised multicentre&#xD;
      study.&#xD;
&#xD;
      The first scheme is a radiological circuit with opacification using contrast media injection.&#xD;
&#xD;
      The second scheme is radio-clinical with a chest X-ray to check the correct functioning of&#xD;
      the CVC followed by a rapid infusion of physiological serum.&#xD;
&#xD;
      The patient management is compared for the two schemes in term of delay (delay from start to&#xD;
      end time of patient management). The safety and the cost of both schemes is compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the delay between randomisation (determination of the lack of blood return) and the decision to initiate or not the chemotherapy protocol on the same day, for both procedures</measure>
    <time_frame>1 day</time_frame>
    <description>Time between randomisation and the decision to initiate or not the chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medico-economic evaluation of both procedures</measure>
    <time_frame>3 months</time_frame>
    <description>Average cost of the patient management for each procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medico-economic evaluation of both procedures</measure>
    <time_frame>3 months</time_frame>
    <description>Number of new lack of catheter blood return events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medico-economic evaluation of both procedures</measure>
    <time_frame>3 months</time_frame>
    <description>Number of complications events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the frequency of recurrence of lack of CVC blood return</measure>
    <time_frame>3 months</time_frame>
    <description>Number of new events of lack of CVC blood return</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the frequency of recurrence of new re-opacification events</measure>
    <time_frame>3 months</time_frame>
    <description>Number of new CVC re-opacification events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the frequency of CVC replacement</measure>
    <time_frame>3 months</time_frame>
    <description>Number of new catheter replacements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantify systemic CVC infectious complications</measure>
    <time_frame>14 days</time_frame>
    <description>Number of Systemic CVC infectious complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess allergic reactions</measure>
    <time_frame>24 hours</time_frame>
    <description>Number of Allergic reactions requiring at least oral therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess renal impairment</measure>
    <time_frame>28 days</time_frame>
    <description>Increase in creatinine to &gt; 1.5 times the most recent screening value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the treatment delay due to CVC blood return</measure>
    <time_frame>1 day</time_frame>
    <description>Number of CVC blood return that led to delay the treatment to the day after</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Catheter Dysfunction</condition>
  <arm_group>
    <arm_group_label>Opacification</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Contrast agent injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Physiological serum injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Physiological serum injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Physiological serum injection</intervention_name>
    <description>In case of lack of CVC blood return, Physiological serum is injected in the CVC after Chest X-Ray</description>
    <arm_group_label>Physiological serum injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Contrast agent injection</intervention_name>
    <description>In case of lack of CVC blood return, Contrast agent is injected in the CVC after Chest X-Ray</description>
    <arm_group_label>Opacification</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female or male, Age â‰¥ 18 years at time of study entry.&#xD;
&#xD;
          -  Undergoing systemic chemotherapy on a CVC.&#xD;
&#xD;
          -  Having already received at least one course of treatment without difficulty.&#xD;
&#xD;
          -  Coming for a new course of treatment authorised by the usual biological assessment.&#xD;
&#xD;
          -  First episode of lack of CVC blood return despite the usual positioning and injection-&#xD;
             aspiration manoeuvres&#xD;
&#xD;
          -  No abnormality on inspection or palpation (turning) of the CVC.&#xD;
&#xD;
          -  Patient has valid health insurance.&#xD;
&#xD;
          -  Patient information and signature of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous episode of lack of CVC blood return whether explored or not.&#xD;
&#xD;
          -  Patient currently treated in an interventional therapeutic trial.&#xD;
&#xD;
          -  Patient with a Picc-line implantable device.&#xD;
&#xD;
          -  Suspected CVC infection or thrombosis.&#xD;
&#xD;
          -  Planned chemotherapy with vesicant agent (anthracyclines).&#xD;
&#xD;
          -  Possible CVC disjunction.&#xD;
&#xD;
          -  Allergy to X-ray contrast agent or creatinine clearance below 30ml/min prohibiting an&#xD;
             iodine injection.&#xD;
&#xD;
          -  Pregnant, likely to be pregnant or breastfeeding woman.&#xD;
&#xD;
          -  Persons deprived of their liberty, under a measure of safeguard of justice, under&#xD;
             guardianship or placed under the authority of a guardian.&#xD;
&#xD;
          -  Impossibility of undergoing medical monitoring of the trial for geographical, social&#xD;
             or psychological reasons, social or psychological reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Audrey ROLLOT, MD</last_name>
    <phone>+33 2 40 67 99 00</phone>
    <email>audrey.rollot@ico.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nadia ALLAM, PhD</last_name>
    <phone>+33 2 40 67 98 26</phone>
    <email>nadia.allam@ico.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de CancÃ©rologie de l'Ouest</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>FÃ©lix Le BORGNE, MD</last_name>
      <email>felix.leborgne@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer Sainte Catherine Avignon Provence</name>
      <address>
        <city>Avignon</city>
        <zip>80005</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Philippe DEBOURDEAU, MD</last_name>
      <email>p.debourdeau@isc84.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch Cholet</name>
      <address>
        <city>Cholet</city>
        <zip>49300</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Victor SIMMET, MD</last_name>
      <email>victor.simmet@ch-cholet.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHD La Roche Sur yon</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Paul BORE, MD</last_name>
      <email>paul.bore@chd-vendee.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre EugÃ¨ne Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Bettina BOUTRUCHE, MD</last_name>
      <email>b.boutruche@rennes.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Yves Le Foll</name>
      <address>
        <city>Saint-Brieuc</city>
        <zip>22023</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marc PORTNEUF, MD</last_name>
      <email>marc.porneuf@armorsante.bzh</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Audrey ROLLOT</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Audrey ROLLOT, MD</last_name>
      <phone>+33240679900</phone>
      <email>audrey.rollot@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de St Malo</name>
      <address>
        <city>Saint-Malo</city>
        <zip>35400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHBA Vannes</name>
      <address>
        <city>Vannes</city>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Camille POIRIER, MD</last_name>
      <email>camille.poirier@ch-bretagne-atlantique.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 18, 2021</study_first_submitted>
  <study_first_submitted_qc>October 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lack of CVC blood return</keyword>
  <keyword>Central Venous Catheter (CVC)</keyword>
  <keyword>Day unit</keyword>
  <keyword>Opacification</keyword>
  <keyword>Contrast media</keyword>
  <keyword>Medico-economic evaluation</keyword>
  <keyword>Physiological serum</keyword>
  <keyword>Chest X-ray</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

